Immunicon Corporation

Basic Information

Immunicon Corporation
3401 Masons Mill Rd, Ste 100
Huntingdon Valley, PA, 19006

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Gene Expression in Circulating Tumor Cells

    Amount: $1,089,994.00

    DESCRIPTION (provided by applicant): The informed development of new treatments for cancer would be greatly facilitated if tumor cells could be directly sampled at multiple time points following the a ...

    STTR Phase II 2005 Department of Health and Human Services
  2. Gene Expression in Circulating Tumor Cells

    Amount: $100,000.00

    N/A

    STTR Phase I 2003 Department of Health and Human Services
  3. Analysis of Circulating Cancer Cells Early in Disease

    Amount: $0.00

    DESCRIPTION: (provided by applicant) The long term objective of this proposal is commercialization of a test for the management of cancer. Imm ...

    SBIR Phase I 2001 Department of Health and Human Services
  4. Analysis of Circulating Cancer Cells Early in Disease

    Amount: $309,500.00

    DESCRIPTION: (provided by applicant) The long term objective of this proposal is commercialization of a test for the management of cancer. Imm ...

    SBIR Phase II 2001 Department of Health and Human Services
  5. N/A

    Amount: $100,000.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  6. BIOPROCESSING USING BIORECEPTOR FERROFLUIDS AND HGMS

    Amount: $383,836.00

    THE LONG-TERM OBJECTIVE IS TO DEVELOP A NEW TECHNOLOGY FOR INDUSTRY SCALE AFFINITY SEPARATIONS EMPLOYING PROPRIETARY BIO- RECEPTOR FERROFLUIDS (BR-FF) IN COMBINATION WITH EXISTING HIGH GRADIENT MAGNET ...

    SBIR Phase II 1992 Department of Health and Human Services
  7. BIOPROCESSING CELLS FROM BLOOD USING BR-FF AND HGMS

    Amount: $50,000.00

    THE LONG TERM OBJECTIVE IS TO DEVELOP A NEW TECHNOLOGY FOR INDUSTRY SCALE AFFINITY SEPARATIONS EMPLOYING PROPRIETARY BIO-RECEPTOR FERROFLUIDS (BR-FF) IN COMBINATION WITH EXISTING CONTINUOUS HIGH GRADI ...

    SBIR Phase I 1991 Department of Health and Human Services
  8. BIOPROCESSING USING BIORECEPTOR FERROFLUIDS AND HGMS

    Amount: $50,000.00

    N/A

    SBIR Phase I 1991 Department of Health and Human Services
  9. FEASIBILITY STUDIES FOR DEVELOPING A NOVEL CLINICAL DEVICE ARE PROPOSED.

    Amount: $50,000.00

    FEASIBILITY STUDIES FOR DEVELOPING A NOVEL CLINICAL DEVICE ARE PROPOSED. THIS DEVICE WHICH WOULD USE IMMUNOLOGICAL AND COMPLEMENT REAGENTS IN CONJUNCTION WITH FILTRATION AND/OR ONE OR MORE MAGNETIC RE ...

    SBIR Phase I 1985 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government